<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03498066</url>
  </required_header>
  <id_info>
    <org_study_id>P150946J</org_study_id>
    <nct_id>NCT03498066</nct_id>
  </id_info>
  <brief_title>Beta Blocker Interruption After Uncomplicated Myocardial Infarction</brief_title>
  <acronym>AβYSS</acronym>
  <official_title>Assessment of βeta Blocker Interruption After Uncomplicated mYocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization: The AβYSS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ABYSS is a national, multicenter, randomised, open label trial using the PROBE study design,&#xD;
      that will evaluate the non-inferiority of the interruption of ΒB therapy after an&#xD;
      uncomplicated MI after six months or more of follow-up compared to the continuation of βB&#xD;
      evaluated by the primary endpoint or death, MI, Stroke and rehospitalization for others&#xD;
      cardiovascular reasons.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the outstanding progress made in cardiac care over the last few years, cardiovascular&#xD;
      diseases remain the leading cause of morbidity and mortality in developed countries.&#xD;
&#xD;
      After the initial clinical event, patients are considered to have a chronic disease which&#xD;
      combined with the increasing actual life expectancy patients with CAD are a major source of&#xD;
      expenses due to their life-long treatment and follow-up.&#xD;
&#xD;
      ΒB are prescribed during the initial hospitalisation for MI and in the post-MI phase.&#xD;
      European (European Society of Cardiology, ESC) and American (ACC/AHA) guidelines initially&#xD;
      gave βB therapy a class I recommendation for MI or acute coronary syndrome (ACS) for the&#xD;
      first year of treatment and extended such recommendation without solid data up to 3 years&#xD;
      after MI , . However, there has been no recent clinical trial to evaluate safety and efficacy&#xD;
      of long term ΒB therapy in the contemporary therapeutic era. Taking such lack of evidence in&#xD;
      account and acknowledging that clinical practice has changed, the latest ESC STEMI (2014) and&#xD;
      NSTEMI (2015) Guidelines degraded the recommendation for the use of ΒB in post MI patients&#xD;
      (Class IIa B) during the hospitalization period and they question the validity of its use&#xD;
      after the initial stabilization phase. This was confirmed in the 2017 STEMI Guidelines.&#xD;
&#xD;
      The primary objective of the ABYSS trial is to demonstrate the non-inferiority of the&#xD;
      interruption of ΒB therapy after an uncomplicated MI after six months or more of follow-up&#xD;
      compared to the continuation of βB evaluated by the primary endpoint.&#xD;
&#xD;
      The primary endpoint of the study will be evaluated, with one-year minimum follow-up, and&#xD;
      will be the composite of Major Adverse Cardiovascular Events (MACE) measured at the longest&#xD;
      follow-up including:&#xD;
&#xD;
        -  All-cause death&#xD;
&#xD;
        -  Stroke&#xD;
&#xD;
        -  Myocardial infarction Hospitalisation for other cardiovascular (CV) reason.&#xD;
&#xD;
      It is expected that the interruption of βB therapy will not alter the prognosis of patients&#xD;
      and improve safety and quality of life of patients and considerably reduce healthcare direct&#xD;
      or indirect costs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2018</start_date>
  <completion_date type="Anticipated">August 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 29, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The composite of Major Adverse Cardiovascular Events (MACE)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>including: All-cause death Stroke Myocardial infarction Hospitalisation for other cardiovascular (CV) reason</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All individual parameters of MACE</measure>
    <time_frame>up to 48 months</time_frame>
    <description>All cause death&#xD;
Heart Failure&#xD;
Arrythmia = Ventricular or Supra-Ventricular Tachycardia&#xD;
Syncope, Conduction disorders or PaceMaker Implantation&#xD;
High Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) (Classified by type of MI, including Stent Thrombosis)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Myocardial Infarction (MI) (Classified by type of MI, including Stent Thrombosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation for other CV reason</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Angina, Recurrent ischemia, Coronary Angiography or Coronary; Revascularisation outside of the scope of an MI; Heart Failure; Arrythmia = Ventricular or Supra-Ventricular Tachycardia; Syncope, Conduction disorders or PaceMaker Implantation; High Blood Pressure;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Cardiovascular death</description>
  </other_outcome>
  <other_outcome>
    <measure>Syncope/dizziness requiring a consultation or a hospitalisation.</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Syncope/dizziness requiring a consultation or a hospitalisation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Invasive procedures (catheterisation, percutaneous coronary intervention (PCI), pace-maker or automatic defibrillator implantation, endoscopy…)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Invasive procedures (catheterisation, percutaneous coronary intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>Angina control</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Angina control measured by the CCS grading scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart Rate Control</measure>
    <time_frame>first year only</time_frame>
    <description>Heart Rate Control by Cardiac Frequency during visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood Pressure Control</measure>
    <time_frame>first year only</time_frame>
    <description>Blood Pressure Control by Blood pressure during visit)</description>
  </other_outcome>
  <other_outcome>
    <measure>An Episode of Heart failure</measure>
    <time_frame>up to 48 months</time_frame>
    <description>An Episode of Heart failure (consultation or Hospitalisation)</description>
  </other_outcome>
  <other_outcome>
    <measure>The quality of life (QoL)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>will be evaluated in every patient by using the questionnaire EQ5D-5L(range 0-1, higher=better health).</description>
  </other_outcome>
  <other_outcome>
    <measure>The composite of:</measure>
    <time_frame>up to 48 months</time_frame>
    <description>Any Death and MI&#xD;
CV death, MI, and stroke.&#xD;
CV death, MI, and urgent coronary revascularisation.&#xD;
CV death, MI, and recurrent ischemia requiring hospitalisation (with or without revascularisation).</description>
  </other_outcome>
  <other_outcome>
    <measure>Anxiety</measure>
    <time_frame>up to12 months</time_frame>
    <description>by using the HADS questionnaire to detect the presence of depression and anxiety ( there is no score; this will be determined by the response selected by the patient with &quot;no&quot; = no discomfort to &quot;a lot&quot; = significant discomfort</description>
  </other_outcome>
  <other_outcome>
    <measure>Erection Dysfunction</measure>
    <time_frame>up to 12 months</time_frame>
    <description>by using the questionnaire IIEF (International Index of Erectile Function) with 5 questions whose answer is graded from 0 to 5 per question</description>
  </other_outcome>
  <other_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>up to 12 months</time_frame>
    <description>by the volume of weekly physical activity</description>
  </other_outcome>
  <other_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>up to 12 months</time_frame>
    <description>by the sport practiced</description>
  </other_outcome>
  <other_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>up to 12 months</time_frame>
    <description>by the participation in competitions or not</description>
  </other_outcome>
  <other_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>up to 12 months</time_frame>
    <description>by the results of stress tests when available</description>
  </other_outcome>
  <other_outcome>
    <measure>Libido</measure>
    <time_frame>up to 12 months</time_frame>
    <description>by the degree of sex drive (self evaluation)</description>
  </other_outcome>
  <other_outcome>
    <measure>Libido</measure>
    <time_frame>up to 12 months</time_frame>
    <description>by the frequency of sex drive (self evaluation)</description>
  </other_outcome>
  <other_outcome>
    <measure>Side effects</measure>
    <time_frame>up to 12 months</time_frame>
    <description>by the presence of Blury Vision</description>
  </other_outcome>
  <other_outcome>
    <measure>Side effects</measure>
    <time_frame>up to 12 months</time_frame>
    <description>by the presence of sensation of cold hands and feets</description>
  </other_outcome>
  <other_outcome>
    <measure>Side effects</measure>
    <time_frame>up to 12 months</time_frame>
    <description>by presence of Insomnia</description>
  </other_outcome>
  <other_outcome>
    <measure>Side effects</measure>
    <time_frame>up to 12 months</time_frame>
    <description>by presence of palpitations</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3700</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Discontinuation of the Betablockers (βB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1850 post-MI patients treated with chronic βB treatment will undergo withdrawal of their βB treatment..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuation of the Betablockers (βB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1850 post-MI patients treated with chronic βB treatment will be continued under their usual βB treatment without modification.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta-blockers withdrawal</intervention_name>
    <description>withdrawal of all type of betablockers</description>
    <arm_group_label>Discontinuation of the Betablockers (βB)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuation of the Betablockers (βB) treatment</intervention_name>
    <description>Use Betablockers treatment</description>
    <arm_group_label>Continuation of the Betablockers (βB)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
        Subjects meeting all of the following criteria will be considered for enrolment into the&#xD;
        study:&#xD;
&#xD;
          1. Male or female +/=18 years of age&#xD;
&#xD;
          2. Current treatment with βB whatever the drug or the dose used&#xD;
&#xD;
          3. Prior acute myocardial infarction 6 months or more before randomisation defined either&#xD;
             by:&#xD;
&#xD;
             AβYSS protocol, version 3.0 of 25/05/2021 Page 32 / 65&#xD;
&#xD;
               -  An episode of ST elevation MI with ST segment elevation (STEMI) and/or the&#xD;
                  presence of Q wave (Type I MI)&#xD;
&#xD;
               -  an episode of Non ST Elevation MI (NSTEMI) with preferably at least one of the&#xD;
                  followings:&#xD;
&#xD;
                    -  i) a documented hypokinetic or akinetic segment on echo or any other imaging&#xD;
                       technique&#xD;
&#xD;
                    -  ii) segmental hypoperfusion Thallium or any other imaging technique&#xD;
&#xD;
                    -  iii) segmental aspect of necrosis on MRI&#xD;
&#xD;
               -  An episode of silent MI discovered on ECG or Cardiac Imaging. Importantly = The&#xD;
                  mention of an MI on a report is enough to be considered as a prior MI and it is&#xD;
                  not necessary to retrieve the source document and/or documentation of this prior&#xD;
                  MI .&#xD;
&#xD;
          4. Patient affiliated to Social Security&#xD;
&#xD;
          5. Informed consent obtained in writing at enrolment into the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects presenting with any of the following will not be included in the study:&#xD;
&#xD;
               1. Uncontrolled arterial hypertension according to investigator decision&#xD;
&#xD;
               2. Prior episode of heart failure in the past two years of follow-up and/or low left&#xD;
                  ventricular ejection fraction &lt;40% requiring the use of βB;&#xD;
&#xD;
               3. New ACS (in the past 6 months) including UA/NSTEMI and STEMI;&#xD;
&#xD;
               4. Persistent angina or ischemia (&gt;10% viable myocardium) requiring the use of βB;&#xD;
&#xD;
               5. Prior episode of ventricular or supraventricular arrhythmia in the past year of&#xD;
                  follow-up requiring the use of ΒB;&#xD;
&#xD;
               6. Treatment with other investigational agents or devices within the previous 30&#xD;
                  days, or previous enrolment in this trial.&#xD;
&#xD;
               7. Pregnant Women or breast feeding women&#xD;
&#xD;
               8. Patient under legal protection (protection of the court, or in curatorship or&#xD;
                  guardianship).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanne SILVAIN, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>APHP / Institut de Cardiologie, Pitié-Salpêtrière Hospital, Paris (APHP) / ACTION Study Group / Sorbonne Université Paris-France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanne SILVAIN, MD-PhD</last_name>
    <phone>01 42 16 29 61</phone>
    <email>johanne.silvain@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gilles MONTALESCOT, MD-PhD</last_name>
    <phone>01 42 16 30 07</phone>
    <email>gilles.montalescot@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cardiologie - USIC - Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanne SILVAIN, MD</last_name>
      <phone>33 1 42 16 30 01</phone>
      <email>johanne.silvain@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Gilles MONTALESCOT, MD, PhD</last_name>
      <phone>33 1 42 16 30 07</phone>
      <email>gilles.montalescot@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>April 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2018</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Beta-Blockers</keyword>
  <keyword>Stable Coronary Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make IPD available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

